Vanguard Group’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-1,066,587
| Closed | -$156K | – | 4129 |
|
|
2019
Q4 | $156K | Sell |
1,066,587
-482,685
| -31% | -$65.8K | ﹤0.01% | 3970 |
|
|
2019
Q3 | $232K | Buy |
1,549,272
+297,222
| +24% | +$53.6K | ﹤0.01% | 3943 |
|
|
2019
Q2 | $201K | Buy |
1,252,050
+566,497
| +83% | +$115K | ﹤0.01% | 3976 |
|
|
2019
Q1 | $134K | Sell |
685,553
-40,240
| -6% | -$8.93K | ﹤0.01% | 3981 |
|
|
2018
Q4 | $508K | Sell |
725,793
-260,797
| -26% | -$291K | ﹤0.01% | 3730 |
|
|
2018
Q3 | $1.21M | Buy |
986,590
+16,138
| +2% | +$18K | ﹤0.01% | 3675 |
|
|
2018
Q2 | $1.08M | Buy |
970,452
+27,368
| +3% | +$41.6K | ﹤0.01% | 3669 |
|
|
2018
Q1 | $1.9M | Buy |
943,084
+183,227
| +24% | +$344K | ﹤0.01% | 3473 |
|
|
2017
Q4 | $911K | Sell |
759,857
-203,972
| -21% | -$278K | ﹤0.01% | 3631 |
|
|
2017
Q3 | $1.21M | Sell |
963,829
-22,878
| -2% | -$29.2K | ﹤0.01% | 3541 |
|
|
2017
Q2 | $1.31M | Sell |
986,707
-252,718
| -20% | -$365K | ﹤0.01% | 3508 |
|
|
2017
Q1 | $2.31M | Buy |
1,239,425
+83,673
| +7% | +$379K | ﹤0.01% | 3339 |
|
|
2016
Q4 | $5.99M | Buy |
1,155,752
+73,452
| +7% | +$386K | ﹤0.01% | 2983 |
|
|
2016
Q3 | $6.03M | Buy |
1,082,300
+113,891
| +12% | +$649K | ﹤0.01% | 2912 |
|
|
2016
Q2 | $5.37M | Buy |
968,409
+150,885
| +18% | +$792K | ﹤0.01% | 2945 |
|
|
2016
Q1 | $3.6M | Buy |
817,524
+55,531
| +7% | +$229K | ﹤0.01% | 3132 |
|
|
2015
Q4 | $4.59M | Buy |
761,993
+150,227
| +25% | +$1.02M | ﹤0.01% | 3019 |
|
|
2015
Q3 | $4.78M | Buy |
611,766
+50,387
| +9% | +$391K | ﹤0.01% | 2983 |
|
|
2015
Q2 | $3.44M | Buy |
561,379
+56,853
| +11% | +$441K | ﹤0.01% | 3186 |
|
|
2015
Q1 | $4.06M | Buy |
504,526
+71,219
| +16% | +$537K | ﹤0.01% | 3096 |
|
|
2014
Q4 | $2.19M | Buy |
433,307
+70,507
| +19% | +$348K | ﹤0.01% | 3255 |
|
|
2014
Q3 | $1.88M | Buy |
362,800
+6,665
| +2% | +$43K | ﹤0.01% | 3290 |
|
|
2014
Q2 | $2.77M | Buy |
356,135
+17,696
| +5% | +$125K | ﹤0.01% | 3107 |
|
|
2014
Q1 | $2.36M | Buy |
338,439
+59,884
| +21% | +$468K | ﹤0.01% | 3152 |
|
|
2013
Q4 | $1.67M | Buy |
278,555
+107,541
| +63% | +$703K | ﹤0.01% | 3262 |
|
|
2013
Q3 | $1.33M | Buy |
171,014
+45,430
| +36% | +$211K | ﹤0.01% | 3286 |
|
|
2013
Q2 | $477K | Buy |
+125,584
| New | +$515K | ﹤0.01% | 3495 |
|
Vanguard Group's GNMX Position: Q1 2020 in Review
Vanguard Group sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 1,066,587 shares — an estimated $156K sold.
Vanguard Group first reported a position in GNMX in Q2 2013 and held it in 27 quarters. The position peaked at $6.03M in Q3 2016. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- Vanguard Group reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- Vanguard Group sold 1,066,587 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $156K.
- Vanguard Group first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 27 quarters.
- Vanguard Group's Aevi Genomic Medicine Inc position peaked at $6.03M in Q3 2016.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on Vanguard Group's 13F filing for Q1 2020, filed 15 May 2020.